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Genome-wide association studies (GWAS) have revealed genetic determinants of iron metabolism, but correl-
ation of these with clinical phenotypes is pending. Homozygosity for HFE C282Y is the predominant genetic
risk factor for hereditary hemochromatosis (HH) and may cause liver cirrhosis. However, this genotype has a
low penetrance. Thus, detection of yet unknown genetic markers that identify patients at risk of developing
severe liver disease is necessary for better prevention. Genetic loci associated with iron metabolism (TF,
TMPRSS6, PCSK7, TFR2 and Chr2p14) in recent GWAS and liver fibrosis (PNPLA3) in recent meta-analysis
were analyzed for association with either liver cirrhosis or advanced fibrosis in 148 German HFE C282Y
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homozygotes. Replication of associations was sought in additional 499 Austrian/Swiss and 112 HFE C282Y
homozygotes from Sweden. Only variant rs236918 in the PCSK7 gene (proprotein convertase subtilisin/kexin
type7)wasassociatedwithcirrhosisoradvancedfibrosis (P 5 1.02 3 1025) in theGermancohortwithgenotypic
odds ratios of 3.56 (95% CI 1.29–9.77) for CG heterozygotes and 5.38 (95% CI 2.39–12.10) for C allele carriers.
Association between rs236918 and cirrhosis was confirmed in Austrian/Swiss HFE C282Y homozygotes (P 5
0.014; ORallelic 5 1.82 (95% CI 1.12–2.95) but not in Swedish patients. Post hoc combined analyses of German/
Swiss/Austrian patients with available liver histology (N 5 244, P 5 0.00014, ORallelic5 2.84) and of males only
(N 5 431, P 5 2.17 3 1025, ORallelic 5 2.54) were consistent with the premier finding. Association between
rs236918 and cirrhosis was not confirmed in alcoholic cirrhotics, suggesting specificity of this genetic risk
factor for HH. PCSK7 variant rs236918 is a risk factor for cirrhosis in HH patients homozygous for the HFE
C282Y mutation.
INTRODUCTION
The rapid progress of genotyping technologies has enabled
genome-wide association studies (GWAS) to be performed for
quantitative laboratory traits, measurable in peripheral blood.
Following the GWAS paradigm, many genetic variants under-
lying a wide range of hematological and metabolic parameters
have been mapped (1–3). However, investigation of these var-
iants in relation to specific human diseases is now required to
translate the laboratory-based findings into clinical medicine.
Hereditary hemochromatosis (HH) is an autosomal recessive
trait (MIM #235200) characterized by elevated serum ferritin
and transferrin saturation, which entails excessive iron accumula-
tion in parenchymal cells of the liver, heart and endocrine organs
(4). Progressive HH is potentially fatal, with a mean survival of
only 1.5 years before the introduction of phlebotomy therapy in
the 1950s. Today, decompensated liver cirrhosis and hepatocellu-
lar carcinoma represent the main causes of HH-related mortality,
mostly due to delayed diagnosis (5,6), whereas adequately treated
patients have a normal life expectancy (7).
The majority of HH cases are due to a variation in HFE gene
located on chromosome 6 (8), and.80% of the patients with clin-
ical HH are homozygous for HFE mutation C282Y (rs1800562,
G845A) (9,10). HH is one of the most prevalent genetic disorders
in Caucasians, with an allele frequency of C282Y of 6.2% and a
homozygosity frequency of 0.38% in a pool of 127,613 indivi-
duals, but shows considerable variation across Europe with
allele frequencies of .10% in Ireland and 0–3% in Mediterra-
nean regions (11). However, the penetrance of C282Y is low. In
a family-based screening, elevation of liver enzymes was
observed in ,30% of male homozygotes (12), and cirrhosis
was present in only 6% of males and 2% of females (13). A
population-based study revealed mildly elevated liver enzymes
or liver disease in ,10% of C282Y homozygotes (14), and the
estimated prevalence of clinical HH was as low as 1%. Other
studies reported liver disease inup to16% of C282Y homozygotes
(15). Studies on the penetrance in C282Y homozygote relatives of
index cases with HH showed that 38% had at least one
disease-related condition, particularly, in males (16). In addition
to environmental factors, such as diet, alcohol consumption and
coexisting chronic viral hepatitis, the course of HH-associated cir-
rhosis may be further modulated by host factors such as gender,
age, obesity and additional genetic variants (4,11).
Genes associated with iron metabolism represent obvious
candidates for the modulation of the iron overload and/or liver
disease phenotype in HH. Several genetic analyses of iron me-
tabolism have been published that identified variants associated
with markers of iron status, such as an association of transferrin
(TF) variants with serum ferritin levels (17), and of type II trans-
membrane serine protease 6 (TMPRSS6) mutations with hemo-
globin, serum iron and transferrin saturation (18,19). A recent
meta-analysis of five GWAS of soluble transferrin receptor
(sTfR) and ferritin revealed a novel association between sTfR
and variation in the proprotein convertase 7 (PCSK7) gene
(20). In addition, mutations in the TFR2 gene were identified
as a cause of hemochromatosis type 3 (HFE3, MIM:604250)
(21). Another locus on chromosome 2p14, tagged by SNP
rs2698530, was implicated in iron deficiency (22). In addition,
variant I148M (rs738409 C/G) within the gene coding for
patatin-like phospholipase domain containing 3 (PNPLA3)
was shown to promote the risk of developing liver fibrosis and
cirrhosis in nonalcoholic fatty liver disease patients in a recent
meta-analysis (23).
Here, we demonstrate that PCSK7 variation is a strong host
risk factor of liver cirrhosis in HH patients homozygous for
C282Y.
RESULTS
Analysis of association with liver cirrhosis in hereditary
hemochromatosis
Selected genetic variants recently robustly associated with iron
metabolism in previous studies are listed in Table 1. For the
present study, these variants were subjected to an allelic associ-
ation test inGermanHHpatients,adopting a Bonferroni-corrected
significance level of 0.008 (six tests). An overview of the cohorts
utilized for discovery, replication and post hoc subgroup analyses
efforts is shown in Table 2. Any additional tests were performed
post hoc in the combined German/Austrian/Swiss sample set.
All HH patients were confirmed as being HFE C282Y homozy-
gous. The clinical diagnosis of liver cirrhosis or advanced (stage
5 or 6) fibrosis compatible with cirrhosis on biopsy was used for
the definition of ‘cases’ in the German, Austrian and Swiss
samples. Patients without cirrhosis on biopsy and patients
without clinical signs of liver fibrosis who did not undergo liver
biopsy because of a clinically mild presentation were classified
as ‘controls’. Among the six lead variants tested, only rs236918
(PCSK7) was found to be significantly associated with liver
disease (P ¼ 1.02× 1025; Padjusted¼ 0.0044) in German HH
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patients (Table 1). Odds ratio estimates were 3.56 (95% CI 1.30–
9.77) for CG heterozygosity and 4.89 (95% CI 1.9–12.5) for car-
riage of the C allele. The frequency of the rs236918 C allele of was
25% in German cirrhotic patients (N ¼ 28) compared with 5.8%
in German non-cirrhotics (N ¼ 120). All other genetic variants
showed no association with liver cirrhosis. None of the additional
tested tagging variants yielded nominal significant association
findings neither in the adjusted nor in the unadjusted analyses
all P. 0.1 (Supplementary Material, Table S1).
Replication in Austrian and Swiss C282Y homozygote
patients
Association of PCSK7 rs236918 C with cirrhosis in German
patients was replicated independently in 499 Austrian/Swiss
C282Y homozygotes and again found significantly associated
with cirrhosis (P ¼ 0.014, Padjusted (sex and age) ¼ 0.028)
(Table 3). Odds ratio estimations were 1.82 (95% CI 1.03–
3.21) for CG heterozygosity, 1.90 (95% CI 1.09–3.29) for C
allele carriage and 3.43 (95% CI 0.61–19.2) for CC homozygos-
ity thereby confirming the initial finding with the C allele being
over-represented in cirrhotics.
Association findings in Swedish C282Y homozygotes
Swedish cirrhotic (N ¼ 8) and non-cirrhotic patients (N ¼ 104)
were classified based on liver biopsy results as previously
described (24). An age- and sex-adjusted analysis yielded an
over-representation of the C risk allele in Swedish cirrhotic
patients with a similar odds ratio [ORadjusted ¼ 1.75 (95% CI
0.34–9.16), Padjusted ¼ 0.5] as obtained in the replication ana-
lysis performed in the Austrian/Swiss sample set. However,
formal replication and statistical significance could not be
achieved in the full Swedish sample owing to the low number
of cirrhosis patients (N ¼ 8, Table 3).
Post hoc analysis of disease risk in German, Austrian
and Swiss patients
Allpost hoc analyses were performed in the combined sample set
of German, Austrian and Swiss HH patients (Table 4) as an eth-
nically relatively homogenous sample. A consistent association
betweenPCSK7 rs236918 C and cirrhosis (Ishak fibrosis stages 5
and 6) was also detected in the subgroup of 244 patients who
underwent a liver biopsy prior to therapy [P ¼ 1.41 × 1024,
allelic OR ¼ 2.84 (95% CI 1.63–4.94) and 3.10 (95% CI
1.58–6.08) for CG heterozygosity]. An overview of the risk
allele frequency ofPCSK7 in the different patients groups is pro-
vided in Figure 1. In further post hoc analyses, the subgroup of
biopsied patients without fibrosis (stage 0; n ¼ 60) showed a
lower frequency (5.8%) of allele C than all non-cirrhotic patients
with fibrosis stages 1 to 4 (9.2%; n ¼ 92). When cirrhotic (n ¼
93) and non-cirrhotic male patients (n ¼ 338) were compared
in a male-only analysis, the association with rs236918 remained
highly significant [P ¼ 2.17 × 1025, ORallelic ¼ 2.54 (95% CI
1.63–3.96)] even after controlling for advanced age by logistic
regression analyses [Padjusted ¼ 1.96 × 1024, ORadjusted ¼ 2.51
(95% CI 1.54–4.07)].
Ferritin levels in C282Y homozygotes with cirrhosis (median:
2760 ng/ml) were higher than those in non-cirrhotic individualsT
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(median: 960 ng/ml), as expected. However, no significant asso-
ciation between ferritin level and PCSK7 genotype was
observed, neither in the non-cirrhotic individuals (mean:
1539 ng/ml in C carriers; 1322 ng/ml in wild-type homozygotes,
t-test: P ¼ 0.191) nor in the HH patients with liver cirrhosis
(mean: 3006 ng/ml in C carriers, 3711 ng/ml in wild-type homo-
zygotes, P ¼ 0.22). An analysis of ferritin levels in the total
cohort of 647 patients produced no evidence of association
(mean 1879 ng/ml in C carriers versus 1594 ng/ml in wild-type
individuals, P ¼ 0.12). A male-only analysis of ferritin levels
and carriage of re236918 C allele in the total cohort (N ¼ 431
male patients) also provided no evidence of association
(mean 2231 ng/ml in C carriers versus 2006 ng/ml in wild-type
individuals, P ¼ 0.56). Similarly, no association between the
PCSK7 rs236918 C allele and transferring saturation was
detected.
Table 2. Cohorts of HFE C282Y homozygous HH patients used in this study
Patient sample Cases Controls
N % Male Age Ferritin (ng/ml) N % Male Age Ferritin (ng/ml)
Discovery cohort
Germany 28 89 61 2757 120 63 51 1142
Replication cohorts
Austria/Switzerland 73 93 60 2795 426 61 50 914
Sweden 8 75 70 2600 104 70 61 705
Post hoc analyses cohorts
Germany/Austria/Switzerland: biopsy only 92 91 60 2765 152 64 52 1200
Germany/Austria/Switzerland: male only 93 100 60 2690 338 100 49 1113
Cases and controls were defined based on the presence of liver cirrhosis in the German, Austrian and Swiss samples. Medians are given for age and ferritin levels.
Table 3. Genetic analysis of liver disease in the Austrian/Swiss and Swedish
replication samples
PCSK7 rs236918 Switzerland/Austria Sweden
All patients All patients (all biopsied)
N total (cases/controls) N ¼ 499 (73/426) N ¼ 112 (8/104)
MAF(C)C282Y/C+ 0.171 0.125
MAF(C)C282Y/C2 0.102 0.082
Pallelic
∗ 0.014 0.55
Padjusted
∗∗ 0.028 0.50
ORadjusted 1.85 (1.07–3.21) 1.75 (0.34–9.16)
ORallelic 1.82 (1.12–2.95) 1.61 (0.34–7.66)
ORheterozygosity 1.82 (1.03–3.35) 1.95 (0.36–10.61)
ORhomozygosity 3.43 (0.61–19.21) NA
The allelic P-value refers to cirrhosis, followed by logistic regression analysis
with adjustment for sex and age. The values in parentheses are 95% CI. C+ and
C2 indicate the presence and absence of cirrhosis, respectively. NA, calculation
not possible.
∗P (allelic, x2 test) nominal; ∗∗P-value adjusted for sex and age; ORadjusted under
additive model (adjusted for sex and age).
Table 4. Combined post hoc risk analysis in German, Austrian and Swiss
Patients
PCSK7 rs236918 Germany/Switzerland/Austria
post hoc analysis Biopsy only Male only
N total (cases/controls) N ¼ 244 (92/152) N ¼ 431 (93/338)
MAF(C)C282Y/C+ 0.196 0.204
MAF(C)C282Y/C2 0.079 0.092
Pallelic
∗ 0.00014 2.17 × 10–5
Padjusted
∗∗ 0.015 1.96 × 10–4
ORadjusted 2.07 (1.15–3.72) 2.51 (1.54–4.07)
ORallelic 2.84 (1.63–4.94) 2.54 (1.63–4.94)
ORheterozygosity 3.10 (1.58–6.08) 2.33 (1.37–3.96)
ORhomozygosity 3.58 (0.83–15.46) 7.75 (1.80–33.31)
The allelicP-value refers to cirrhosis. The values in parentheses are 95% CI. C+
and C2 indicate the presence and absence of cirrhosis, respectively. NA,
calculation not possible.
∗P (allelic, x2 test) nominal; ∗∗P (adjusted for sex and age); ORadjusted under
additive model (adjusted for sex and age).
Figure 1. Allele frequency of PCSK7 rs236918 C across study populations and
subgroups. NC, normal controls; ALD, cirrhosis on the basis of alcoholic liver
disease; HH, hereditary hemochromatosis as defined by C282Y homozygosity.
P-values are given for an allelic test of association.
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Allele frequencies in the general population and patients
with alcoholic liver cirrhosis
To delineate the possible role of the tested genetic variants
outside of HH, allele frequencies of all markers were also deter-
mined in unaffected individuals with normal liver enzyme levels
and with no clinical evidence of liver disease. The frequency of
the PCSK7 rs236918 C allele (11.5%) among population-based
control individuals from the EMIL (Ulm, Southern Germany,
n ¼ 980) and the SHIP study (Greifswald, Northern Germany,
n ¼ 170) (25,26) was higher than that among HH patients
without apparent liver lesions (fibrosis stage 0) (5.8%, P ¼
0.054), higher than in HH controls (9.2%,P ¼ 0.046) and signifi-
cantly lower than in HH patients with confirmed liver cirrhosis or
advanced fibrosis (19.3%, P ¼ 0.001). A similar NC allele fre-
quency as in German population controls (10.6%) was observed
in the Swedish population, which was also higher than that in
Swedish HH controls (8.2%, P ¼ 0.285, Fig. 1).
Evaluation of thePCSK7 allele distribution in patients with al-
coholic cirrhosis [n ¼ 203; for details see Stickel et al. (27)]
revealed a similar frequency of the C allele as in the control popu-
lation (11.8%, P ¼ 0.86), indicating a disease-specific role of
PCSK7 in modifying the risk of progressive liver disease in
C282Y homozygous HH patients.
In silico assessment of PCSK7 rs236918
In order to explore the putative functional effect of the rs236918
risk variant, we performed an in silico analysis at the PCSK7
locus using data from ENCODE (28). The data contained
therein point to a possible role of this variant in transcriptional
regulation of PCSK7 because the degree of histone H3 lysine
27 acetylation (H3K27ac) at CpG islands is associated with tran-
scriptional activation. The analysis of chromatin state showed a
cell-specific H3K27ac enrichment at PCSK7 distal to the pro-
moter. Rs236918 is located within this region that is predicted
to serve as a strong enhancer in three of nine cell lines investi-
gated by ENCODE (Supplementary Material, Fig. S1), thereby
providing indirect evidence for a possible cis-effect of
rs236918 on PCSK7 expression.
DISCUSSION
The present data identify the PCSK7 rs236918 C allele as a
genetic risk factor for cirrhosis in patients homozygous for
HFE gene mutation C282Y. Apart from providing a partial ex-
planation for the variability in clinical phenotype observed
among homozygous carriers of C282Y, our result may potential-
ly impact on screening of HH patients, particularly of males. Car-
riage of PCSK7 rs236918 C allele may help to identify those at
risk for progressive liver disease, and thereby open new research
avenues for a better understanding of the molecular pathophysi-
ology of HH. The lower frequency of rs236918 C risk allele
among C282Y homozygotes without liver cirrhosis, compared
with population controls, and the lack of association with alco-
holic cirrhosis further illustrates how the phenotypic effect of
this variant depends on the presence of the HFE mutation and
points to a strong gene–gene interaction (Fig. 1).
Previous population studies have revealed that progressive
liver disease affects only a minority of C282Y homozygotes
(11,14). One obvious approach to find potential genetic disease
modifiers is the evaluation of genes associated with conditions
that are closely related to the disease of interest. An attractive
strategy is to select these genes from GWAS of quantitative
traits such as serum laboratory parameters employed in the
routine diagnosis of the disease under scrutiny. Along this line,
genetic variants significantly associated with markers of iron
metabolism in previous GWAS were investigated in the
present study. A multicenter cohort of HH patients recruited
between 1997 and 2011 at several tertiary referral centers in
Germany was used as a ‘discovery sample’. Subsequent replica-
tion of association findings was then sought in an independent
multicenter cohort of HH patients from Austria, Switzerland
and Sweden. In retrospective multicenter studies, robust defin-
ition of the primary endpoint is pivotal. Considering that patients
homozygous for the C282.Y mutation face a higher all-cause
morbidity and mortality than heterozygotes or wild-type homo-
zygotes, with end-stage liver cirrhosis and hepatocellular carcin-
oma being the predominant causes of death (6,7,29), we focused
on the presence or absence of liver disease. For the latter, we
chose an unambiguous phenotype, namely advanced fibrosis
or cirrhosis as diagnosed on biopsy or liver cirrhosis unequivo-
cally established by clinical and imaging studies that could be
assessed consistently across centers. This might be one possible
reason why the PCSK7 risk variant identified here yielded very
similar odds ratio for liver disease in different subgroups of
HH patients.
Males with C282Y+/+ are more prone to develop iron over-
load and consecutive liver damage than females, mainly because
women have regular blood losses owing to menstruation.
However, iron accumulation commences similarly in postmeno-
pausal women. Thus, premenopausal women with C282Y+/+
carriage may constitute a confounding factor that could skew
genotype–phenotype associations. We therefore performed a
post hoc analysis of male subjects only in the combined
German/Austrian/Swiss cohort, which confirmed the associ-
ation of the PCSK7 rs236918 C allele and advanced liver fibro-
sis/cirrhosis. The presence of the PCSK7 rs236918 C allele thus
represents a significant risk marker in the subgroups of males
who are most susceptible to develop liver disease underlining
its potential impact on population screening strategies.
When restricting our analysis to those subjects in the total
cohort of German/Austrian/Swiss patients in whom liver hist-
ology data staged for fibrosis (as a quantifiable trait) were avail-
able, post hoc calculations confirmed PCSK7 rs236918 C allele
as significantly associated with cirrhosis, showing a gradual in-
crease in the allele frequency along with progression of fibrosis.
The loci selected for our study (i.e. TF, TMPRSS6, PCSK7,
TFR2 and Chr2p14) were identified in earlier studies, which
focused on different laboratory parameters of iron metabolism
(Table 1). The risk locus for liver disease in HH patients identi-
fied in the present study (PCSK7) yielded the strongest signal in a
study investigating sTfR (20). Given the strong association of the
PCSK7 locus with sTfR levels in the iron metabolism GWAS,
this variant could indeed be functionally relevant. Further in
silico analyses show that PCSK7 rs236918 is located within a
region distal to the promoter that is predicted to serve as an en-
hancer in three of nine cell lines investigated by ENCODE.
We thus speculate that rs236918 might affect the expression of
PCSK7 in a cis-regulatory fashion.
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The gene product ofPCSK7 (proprotein convertase subtilisin/
kexin type 7, PC7/8) is a convertase, similar to furin (PCSK3),
that belongs to a larger family of proteases (30) and that is char-
acterized by a distinct mode of intracellular assembly (31).
Oexle and coworkers have recently demonstrated a significant
genome-wide association of PCSK7 SNP rs236918 with sTfR
levels (20). It was speculated that PCSK7, being a furin-like
convertase, functions in iron homeostasis by generating soluble
hemojuvelin (sHJV) from cellular hemojuvelin (32,33), thereby
modulating hepcidin activation. Further, direct shedding of the
TfR was considered another possibility (20). Regarding the
latter, Guillemot et al. have convincingly demonstrated in cell
culture experiments using several hepatoma cell lines and
primary murine hepatocytes coexpressing both human TfR1 and
PCSK7 that PCSK7 is the only convertase that sheds TfR,
whereas hepcidin is specifically processed by furin, but not by
PCSK7 (34). A subsequent in vitro study in HeLa and LoVo
cells found no evidence of PCSK7 cleavage activity on HJV sup-
porting the role of PCSK7 as an exclusive sheddase of TfR (35).
Considering the association ofPCSK7SNP rs236918 with cir-
rhosis in C282Y homozygotes, it would be important to decipher
the molecular mechanism of how this variant may stimulate the
production of excess hepatic scar tissue. There are no human or
mammalian data on this issue, but a recent study in zebrafish
demonstrated the ability of PCSK7 to increase both mRNA ex-
pression and proteolytic cleavage of transforming growth
factor beta 1 (TGFb1), the premier profibrogenic cytokine and
activator of hepatic stellate cells/portal myofibroblasts (HSC/
MFB) as the crucial source of collagenous matrix in liver fibro-
genesis (36). Interestingly, an earlier study identified a specific
TfR on isolated activated rat HSC/MFB, and treatment of cells
with transferrin caused their activation and upregulation of
procollagen-type gene expression indicating a significant role
of TfR in iron-mediated liver fibrogenesis (37), Further research
should therefore elucidate whether PCSK7-mediated TGFb1 ac-
tivation plays a significant role in human liver fibrosis and
whether the postulated gain of function variant PCSK7
rs236918 leads to increased TGFb1 signaling and excess
matrix formation.
Other markers associated primarily with serum transferrin
levels (TF) (17), serum iron concentration (TMPRSS6) (18),
total iron levels (TFR2) (18), iron deficiency (2p14) (22) and
liver fibrosis (PNPLA3) (23) were negative with regard to this
phenotype.
Regarding TMPRSS6, our data conflict with findings from a
recent genetic case–control study (38) including 315 Italian HH
patients with C282Y homozygosity (n ¼ 163), compound hetero-
zygotes (n ¼ 27) and HFE genotypes not commonly associated
with HH (n ¼ 125). Authors found the p.A736V TMPRSS6 poly-
morphism to confer protection against clinical HH, but independ-
ent replication was not demonstrated. In addition, subgroups were
rather small, particularly cirrhotic patients (n ¼ 40), and C282Y
homozygotes afflicted by coexisting confounders (viral hepatitis
and alcohol abuse). Moreover, the frequency of the protective
p.A736V TMPRSS6 CC genotype was similar in clinically
healthy and diseased HH patients and only significantly different
when compared with healthy control. Ethnic differences between
Italian and Northern European subjects may account for the dis-
crepancy between these and our findings.
In conclusion, our study shows how genetic markers of iron
metabolism obtained through genome-wide scanning can be
related to a clinically relevant trait, such as advanced liver fibro-
sis in HH. Admittedly, our study is limited by its retrospective
nature preventing uniform sampling and more extensive pheno-
typing and explored only a small range of hypotheses (defined by
previous iron metabolism GWAS). This notwithstanding, the
large effect size of the PCSK7 variant has allowed its discovery
as the first disease modifier in HH. The potential for predictive
testing in HH – a disorder that is easily treated and prevented
by phlebotomy – has been thoroughly studied and discussed,
and the current consensus is that population genetic screening
is not indicated in HH (11,13,39). However, this view might
change in the future with the possibility to genetically identify
subgroups of HH who carry a high risk of progressive liver
disease. To further this development, additional large-scale
and population-based studies are however needed to confirm
and better define the impact of PCSK7 and other variants on
HH phenotypes.
MATERIALS ANDMETHODS
Ethics approval
The study received Ethics committee approval from of all par-
ticipating centers in which patients were recruited for the
study, and only subjects were included who had given written
consent to have their DNA tested in the context of a retrospective
scientific study.
Patients
Recruitment of consecutive patients homozygous for the C282Y
mutation from Germany (N ¼ 148), Switzerland (N ¼ 60),
Austria (N ¼ 439) and Sweden (N ¼ 112) commenced in 1997
when routine genotyping for the HFE mutation became avail-
able in Erlangen, Rostock, Kiel, Frankfurt (Germany), Berne
(Switzerland), Innsbruck, Salzburg, Oberndorf, Vienna, Graz
(Austria), O¨rebro and Stockholm (Sweden). All patients
included in the present study were confirmed homozygotes for
the HFE C282Y mutation.
Phenotypes
Patients were clinically characterized as described earlier
(40,41). Briefly, each patient underwent clinical examination, la-
boratory testing and abdominal ultrasound or computed tomog-
raphy. In patients with confirmed or suspected cirrhosis, upper
gastrointestinal endoscopy was performed. Chronic viral hepa-
titis was excluded in all patients by testing for hepatitis B virus
surface antigen and anti-HBc, and by third-generation hepatitis
C virus antibody ELISA. Daily alcohol intake of .30 g for
men and.20 g for women led to exclusion. No clinical or sero-
logical signs of autoimmune liver disease were present. All
patients and controls were European Caucasians and originated
from Austria, Germany, Switzerland and Sweden.
Pretreatment liver biopsies (N ¼ 244) were scored according
to Ishak et al. (42). The presence of cirrhosis was established
with fibrosis stages 5 and 6, or if there was unequivocal evidence
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for liver damage (i.e. elevated liver enzyme activity, impaired
coagulation, low serum albumin concentration and low platelet
count) together with at least one of the following: (a) cirrhosis-
related complications including encephalopathy, ascites or
hepatocellular carcinoma, (b) cirrhosis on abdominal ultrasound
and/or computed tomography and (c) esophageal varices in
upper gastrointestinal endoscopy.
Swedish patients (n ¼ 112) were diagnosed based upon
C282Y homozygosity and laboratory parameters, including
serum liver enzyme activities, bilirubin, prothrombin time,
serum albumin and ferritin concentrations. From all patients,
scored liver histologies were available and cirrhosis was estab-
lished if biopsies revealed fibrosis stages 5 and 6 (42). Patients
with alcoholic liver cirrhosis were identified as reported (27).
SNP selection
Loci known to be associated at genome-wide significance level
with markers of iron status, namely ferritin, transferrin satur-
ation, serum iron and soluble transferrin receptor and liver fibro-
sis were selected from previous GWAS and meta-analysis
studies (17–23).
Additional tagging SNPs were selected for all iron loci from
HAPMAP (www.hapmap.org) by the automated selection of
haplotype tagging SNPs for Caucasians from the CEU dataset
(settings – Mendel errors: 0, minor allele frequency: 0.1, HWE
cutoff: 0.01) by using the tagger algorithm available through Hap-
loview (http://www.broad.mit.edu/mpg/haploview/; http://www.
broad.mit.edu/mpg/tagger/), using pairwise SNP selection with a
minimum r2 threshold of 0.8. We additionally selected SNPs
based on functional impact according to the literature. Including
the lead marker, this resulted in a selection of five SNPs for
PCSK7, seven SNPs for TMPRSS6, four SNPs for TFR2, five
SNPs for TF and four SNPs for theChr2p14 locus. This selection
captures a high degree (.80%) of the known common variability
in these loci. ForPNPLA3, only the lead marker I148M (rs738409
C/G) was selected.
Genotyping and statistical analysis
Genotyping for TF (rs3811647), TMPRSS6 (rs855791), PCSK7
(rs236918), TFR2 (rs7385804) and for rs2698530 on chromo-
some 2p14 was performed using Sequenom and Taqmanw
allelic discrimination assays (43). All process data was logged
and administered using a database-driven LIMS (44). Contin-
gency tables were analyzed with a x2 test or Fisher’s exact test,
and differences between numerical values were evaluated
using a t-test as implemented in R (www.r-project.org).
Nominal P-values were reported for all tests. Primary associ-
ation findings andpost hoc analysis were also verified by control-
ling for advancing age and male gender as known risk factors for
hemochromatosis using a multivariate logistic regression ana-
lysis with genotypes (additive model, defined as 0, 1 or 2
copies of the C allele), age and gender as independent variables.
All logistic regression analyses were performed with SPSS soft-
ware (version 21.0; SPSS, Inc., Chicago, IL, USA).
The investigated patient sample provides a power of .87%
for the detection of a 5-fold higher risk of cirrhosis and .50%
power for the detection of a 3-fold higher risk of cirrhosis at
risk allele exposure level of 0.3 in controls. The Type I error
probability was set to be 0.008, corresponding to the Bonferroni-
corrected significance level of 0.05 for six tests. Power calcula-
tions were performed with PSpower (45).
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